Abbott Laboratories (ABT)
86.30
-0.87 (-1.00%)
NYSE · Last Trade: May 6th, 9:25 PM EDT
Detailed Quote
| Previous Close | 87.17 |
|---|---|
| Open | 87.55 |
| Bid | 86.32 |
| Ask | 86.45 |
| Day's Range | 86.15 - 87.69 |
| 52 Week Range | 86.15 - 139.06 |
| Volume | 12,456,257 |
| Market Cap | 151.11B |
| PE Ratio (TTM) | 23.14 |
| EPS (TTM) | 3.7 |
| Dividend & Yield | 2.520 (2.92%) |
| 1 Month Average Volume | 13,296,257 |
Chart
About Abbott Laboratories (ABT)
Abbott Laboratories is a global healthcare company that specializes in the development of a wide range of medical devices, diagnostics, nutrition products, and pharmaceuticals. The company focuses on innovation to improve patient outcomes and enhance the quality of life for individuals worldwide. Abbott is known for its advancements in areas such as cardiovascular care, diabetes management, and nutrition science, providing essential tools and solutions that support healthcare professionals and patients in managing various health conditions. With a strong commitment to research and development, Abbott continually seeks to address unmet medical needs and contribute to the advancement of healthcare globally. Read More
News & Press Releases
They have combined for 118 years of consecutive dividend increases.
Via The Motley Fool · May 6, 2026
These stocks pay more than double the S&P 500 average and have modest valuations relative to the overall market.
Via The Motley Fool · May 6, 2026
These stocks check off multiple boxes for income investors.
Via The Motley Fool · May 6, 2026
ABBOTT LABORATORIES (NYSE:ABT) Posts Mixed Q1 2026 Results, Cuts Guidance After Exact Sciences Acquisitionchartmill.com
Via Chartmill · April 16, 2026
A rare yield, Dividend King status, and a steady healthcare business may be creating one of its most interesting income setups in years.
Via The Motley Fool · May 3, 2026
This company, which has raised its dividend for 54 consecutive years, is on sale.
Via The Motley Fool · May 2, 2026
Via MarketBeat · April 29, 2026
How does a nearly 3% (and growing) dividend yield sound?
Via The Motley Fool · April 28, 2026
Abbott Labs is a balance of income and growth.
Via Barchart.com · April 23, 2026

They offer investors very different value propositions.
Via The Motley Fool · April 20, 2026
Various concerns weighed on appetite for stocks in recent weeks.
Via The Motley Fool · April 20, 2026
These stocks pay juicy dividends but also offer much more.
Via The Motley Fool · April 19, 2026

Abbott Laboratories (NYSE:ABT) reported upbeat Q1 earnings but lowered its 2026 outlook, including dilution from Exact Sciences acquisition.
Via Benzinga · April 17, 2026
TSMC's Chip Heat Extends the Record Run, Then Netflix Drops a Double Surprise After the Bellchartmill.com
Via Chartmill · April 17, 2026
It essentially met analyst expectations for its inaugural quarter of 2026.
Via The Motley Fool · April 16, 2026
Johnson & Johnson, Abbott Laboratories, and Becton, Dickinson don't fall as far as other healthcare stocks and bounce back faster during economic downturns.
Via The Motley Fool · April 16, 2026
Which S&P500 stocks are moving on Thursday?chartmill.com
Via Chartmill · April 16, 2026
Discover which S&P500 stocks are making waves on Thursday.chartmill.com
Via Chartmill · April 16, 2026
Abbott (ABT) Q1 2026 Earnings Call Transcript
Via The Motley Fool · April 16, 2026
What's going on in today's session: S&P500 gap up and gap down stockschartmill.com
Via Chartmill · April 16, 2026
Healthcare product and device company Abbott Laboratories (NYSE:ABT) announced better-than-expected revenue in Q1 CY2026, with sales up 7.8% year on year to ...
Via StockStory · April 16, 2026
Which S&P500 stocks are moving before the opening bell on Thursday?chartmill.com
Via Chartmill · April 16, 2026
Johnson & Johnson (NYSE: JNJ) delivered a robust first-quarter 2026 earnings report on April 14, 2026, handily beating Wall Street expectations and signaling a successful navigation of the long-feared "Stelara" patent cliff. The healthcare titan reported an adjusted earnings per share (EPS) of $2.70, comfortably ahead of the $2.66
Via MarketMinute · April 15, 2026
Abbott Laboratories (NYSE: ABT) to report Q1 earnings on April 16, expected EPS of $1.15 and revenue of $11B. Acquired Exact Sciences, stock up 0.4%.
Via Benzinga · April 14, 2026